These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 25195562

  • 21. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M.
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [Abstract] [Full Text] [Related]

  • 22. Distinct phenotype of kidney stone formers with renal phosphate leak.
    Dhayat NA, Lüthi D, Schneider L, Mattmann C, Vogt B, Fuster DG.
    Nephrol Dial Transplant; 2019 Jan 01; 34(1):129-137. PubMed ID: 29939320
    [Abstract] [Full Text] [Related]

  • 23. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.
    Ashikaga E, Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Matsumoto K, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T.
    Ther Apher Dial; 2010 Jun 01; 14(3):315-22. PubMed ID: 20609185
    [Abstract] [Full Text] [Related]

  • 24. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, Rentsch KM, Wüthrich RP, Serra AL.
    Kidney Int; 2011 Jan 01; 79(2):234-40. PubMed ID: 20944552
    [Abstract] [Full Text] [Related]

  • 25. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
    Muras K, Masajtis-Zagajewska A, Nowicki M.
    J Clin Endocrinol Metab; 2013 Dec 01; 98(12):E1901-8. PubMed ID: 24092829
    [Abstract] [Full Text] [Related]

  • 26. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
    Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y.
    Clin J Am Soc Nephrol; 2010 Jul 01; 5(7):1268-76. PubMed ID: 20448073
    [Abstract] [Full Text] [Related]

  • 27. Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.
    Asamiya Y, Yajima A, Shimizu S, Otsubo S, Tsuchiya K, Nitta K.
    Osteoporos Int; 2015 Mar 01; 26(3):1017-28. PubMed ID: 25366373
    [Abstract] [Full Text] [Related]

  • 28. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P, Adamczak M, Wiecek A.
    Clin Endocrinol (Oxf); 2014 Apr 01; 80(4):607-12. PubMed ID: 24111496
    [Abstract] [Full Text] [Related]

  • 29. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S, Tsuruya K, Tokumoto M, Yoshida H, Ooboshi H, Kitazono T.
    Nephrology (Carlton); 2015 Sep 01; 20(9):639-45. PubMed ID: 25974190
    [Abstract] [Full Text] [Related]

  • 30. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease.
    Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P.
    J Clin Endocrinol Metab; 2010 Apr 01; 95(4):1741-8. PubMed ID: 20157196
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M.
    Kidney Int; 2011 Jun 01; 79(12):1370-8. PubMed ID: 21389978
    [Abstract] [Full Text] [Related]

  • 33. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A, Kazama JJ, Yamamoto S, Yoshita K, Watanabe Y, Iino N, Narita I.
    Nephron; 2015 Jun 01; 131(3):161-6. PubMed ID: 26551233
    [Abstract] [Full Text] [Related]

  • 34. Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets.
    Alon U, Chan JC.
    J Clin Endocrinol Metab; 1984 Apr 01; 58(4):671-5. PubMed ID: 6546575
    [Abstract] [Full Text] [Related]

  • 35. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.
    Ferrari SL, Bonjour JP, Rizzoli R.
    J Clin Endocrinol Metab; 2005 Mar 01; 90(3):1519-24. PubMed ID: 15613425
    [Abstract] [Full Text] [Related]

  • 36. Renal handling of phosphate in relation to serum parathyroid hormone levels.
    Madsen S, Olgaard K, Ladefoged J.
    Acta Med Scand; 1976 Mar 01; 200(1-2):7-10. PubMed ID: 785962
    [Abstract] [Full Text] [Related]

  • 37. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M, Koch TA, Bregman DB.
    J Bone Miner Res; 2013 Aug 01; 28(8):1793-803. PubMed ID: 23505057
    [Abstract] [Full Text] [Related]

  • 38. Acid Load and Phosphorus Homeostasis in CKD.
    Khairallah P, Isakova T, Asplin J, Hamm L, Dobre M, Rahman M, Sharma K, Leonard M, Miller E, Jaar B, Brecklin C, Yang W, Wang X, Feldman H, Wolf M, Scialla JJ, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.
    Am J Kidney Dis; 2017 Oct 01; 70(4):541-550. PubMed ID: 28645705
    [Abstract] [Full Text] [Related]

  • 39. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP, Bouma-de Krijger A, van Zuilen AD, Bots ML, van den Brand JA, Blankestijn PJ, Wetzels JF, Vervloet MG.
    J Nephrol; 2015 Aug 01; 28(4):477-84. PubMed ID: 25700931
    [Abstract] [Full Text] [Related]

  • 40. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.
    Young A, Hodsman AB, Boudville N, Geddes C, Gill J, Goltzman D, Jassal SV, Klarenbach S, Knoll G, Muirhead N, Prasad GV, Treleaven D, Garg AX, Donor Nephrectomy Outcomes Research (DONOR) Network.
    Am J Kidney Dis; 2012 Jun 01; 59(6):761-9. PubMed ID: 22093959
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.